AbbVie Inc. said Thursday the Food and Drug Administration has approved its vyalev as the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of ...

Around 1,000 people with Parkinson’s disease will be able to access treatment with AbbVie’s Produodopa, the first therapy that can be delivered by a 24-hour subcutaneous infusion pump ...

Previous studies with intravenous immunoglobulin, or IVIG, have raised concerns that symptom improvements might be due to ...

AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...

Gaining approval for subcutaneous Keytruda would expand access ... In its IV form, Keytruda is administered at infusion centers, with the procedure taking approximately 30 minutes, every three ...

11 analysts have shared their evaluations of Insulet PODD during the recent three months, expressing a mix of bullish and ...

About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life ...

If approved, this option would allow patients to begin treatment with under-the-skin or subcutaneous (SC) injections instead ...